Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease

Lukas Vrba; Bernard W. Futscher; Marc Oshiro; George S. Watts; Emmanuel Menashi; Charles Hu; Hytham Hammad; Daniel R. Pennington; Umamaheshwari Golconda; Hemanth Gavini; Denise J. Roe; Rachna T. Shroff; Mark A. Nelson

doi:10.1186/s13148-022-01246-2

Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease

Lukas Vrba, Bernard W. Futscher, Marc Oshiro, George S. Watts, Emmanuel Menashi, Charles Hu, Hytham Hammad, Daniel R. Pennington, Umamaheshwari Golconda, Hemanth Gavini, Denise J. Roe, Rachna T. Shroff, Mark A. Nelson

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients.

Original language	English (US)
Article number	28
Journal	Clinical Epigenetics
Volume	14
Issue number	1
DOIs	https://doi.org/10.1186/s13148-022-01246-2
State	Published - Dec 2022

ASJC Scopus subject areas

Molecular Biology
Genetics
Developmental Biology
Genetics(clinical)

Access to Document

10.1186/s13148-022-01246-2

Cite this

Vrba, L., Futscher, B. W., Oshiro, M., Watts, G. S., Menashi, E., Hu, C., Hammad, H., Pennington, D. R., Golconda, U., Gavini, H., Roe, D. J., Shroff, R. T., & Nelson, M. A. (2022). Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease. Clinical Epigenetics, 14(1), Article 28. https://doi.org/10.1186/s13148-022-01246-2

@article{5e269edb57e6424ebf10209267a3e596,

title = "Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease",

abstract = "We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients.",

author = "Lukas Vrba and Futscher, {Bernard W.} and Marc Oshiro and Watts, {George S.} and Emmanuel Menashi and Charles Hu and Hytham Hammad and Pennington, {Daniel R.} and Umamaheshwari Golconda and Hemanth Gavini and Roe, {Denise J.} and Shroff, {Rachna T.} and Nelson, {Mark A.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1186/s13148-022-01246-2",

language = "English (US)",

volume = "14",

journal = "Clinical Epigenetics",

issn = "1868-7075",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease

AU - Vrba, Lukas

AU - Futscher, Bernard W.

AU - Oshiro, Marc

AU - Watts, George S.

AU - Menashi, Emmanuel

AU - Hu, Charles

AU - Hammad, Hytham

AU - Pennington, Daniel R.

AU - Golconda, Umamaheshwari

AU - Gavini, Hemanth

AU - Roe, Denise J.

AU - Shroff, Rachna T.

AU - Nelson, Mark A.

PY - 2022/12

Y1 - 2022/12

N2 - We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients.

AB - We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85125154242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125154242&partnerID=8YFLogxK

U2 - 10.1186/s13148-022-01246-2

DO - 10.1186/s13148-022-01246-2

M3 - Article

C2 - 35193708

AN - SCOPUS:85125154242

SN - 1868-7075

VL - 14

JO - Clinical Epigenetics

JF - Clinical Epigenetics

IS - 1

M1 - 28

ER -

Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint